Herbalife Ltd. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Basis of Presentation - Additional Information (Detail)

Basis of Presentation - Additional Information (Detail) shares in Millions, $ in Millions		1 Months Ended			3 Months Ended	6 Months Ended	12 Months Ended
	Apr. 17, 2025 USD ($)	Feb. 28, 2026 USD ($)	Apr. 30, 2025 USD ($)	Jul. 31, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($) Product Segment shares	Dec. 31, 2024 USD ($) shares	Dec. 31, 2023 USD ($) shares
Subsidiary Or Equity Method Investee [Line Items]
General and administrative expenses							$ 1,664.3	$ 1,725.6	$ 1,701.0
Other current liabilities							489.8	517.0
Cash outflow							333.3	285.4	357.5
Foreign currency transaction losses							14.5	9.2	18.7
Receivables from credit card company							59.4	53.1
Bad-debt expense							0.0	0.1	0.1
Allowance for doubtful accounts							1.8	2.5
Amortization expense related to debt issuance costs							7.6	7.6	7.1
Unamortized debt issuance cost							24.9	32.5
Long-term debt							1,992.6	2,260.1
Accumulated deficit							(579.7)	(808.0)
Capitalized internal-use software costs							267.1	286.0
Depreciation and amortization of property, plant and equipment							99.4	96.5	$ 88.9
Marketing related intangible assets							310.0	310.0
Goodwill							100.5	$ 87.7
Increase in goodwill balance							12.8
Goodwill acquired during period							7.2
Goodwill foreign currency translation adjustments							$ 5.6
Change in income tax rate							21.00%	21.00%	21.00%
Other operating income							$ 4.8	$ 5.5	$ 10.2
(Gain) Loss on extinguishment of debt							0.0	(10.5)	1.0
Advertising costs							$ 42.1	$ 46.0	$ 54.1
Equity grants with anti-dilutive effect \| shares							15.4	15.4	5.7
Dilutive effect of 2028 Convertible Notes \| shares							0.0	0.0	0.2
Allowances for product returns							$ 2.0	$ 1.8
Number of product categories \| Product							5
Number of geographic regions \| Segment							5
Non-cash capital expenditures							$ 10.1	14.8	$ 27.5
Non-cash borrowings that were used to finance software maintenance							0.0	0.0	2.7
Proceeds from sale of real estate, held for sale				$ 38.0
Real estate held for sale, land, building, and building improvements								34.0
Right-of-use asset and lease liabilities							4.0
Minority interest increase						$ 6.2
Pro2col Software, LLC [Member] \| Subsequent Event [Member]
Subsidiary Or Equity Method Investee [Line Items]
Equity interest percentage		5.00%
Additional equity interest percentage		5.00%
Proceeds from equity interest		$ 7.5
Increased ownership percentage		10.00%
Additional equity interest percentage to be acquired		10.00%
Pruvit
Subsidiary Or Equity Method Investee [Line Items]
Consideration to acquire assets	$ 19.0
HBL Link Bioscience LLC [Member]
Subsidiary Or Equity Method Investee [Line Items]
Consideration to acquire assets			$ 6.5
Ownership interest percentage			51.00%
Link BioSciences Inc [Member]
Subsidiary Or Equity Method Investee [Line Items]
Asset acquisition contingent payments			$ 0.0
Cash paid			6.5
Assets estimated fair value at the acquisition date			12.7
Reduction in cash			6.5
Link BioSciences Inc [Member] \| Goodwill [Member]
Subsidiary Or Equity Method Investee [Line Items]
Assets estimated fair value at the acquisition date			7.2
Secretariat of the federal revenue bureau of brazil [Member]
Subsidiary Or Equity Method Investee [Line Items]
Restricted cash							15.2	15.2
Pro2col Health LLC [Member]
Subsidiary Or Equity Method Investee [Line Items]
Milestones period	10 years
Additional payments	$ 0.0
Contingent Milestone Payments Second [Member] \| Pro2col Health LLC [Member]
Subsidiary Or Equity Method Investee [Line Items]
Maximum milestone contingent payments	46.0
2018 Credit Facility [Member]
Subsidiary Or Equity Method Investee [Line Items]
(Gain) Loss on extinguishment of debt					$ 2.5
Other (Income) Expense, Net [Member] \| Senior Notes Two Thousand Twenty Five [Member] \| 2018 Credit Facility [Member]
Subsidiary Or Equity Method Investee [Line Items]
(Gain) Loss on extinguishment of debt								10.5
Other (Income) Expense, Net [Member] \| Two Thousand Twenty Four Convertible Notes [Member]
Subsidiary Or Equity Method Investee [Line Items]
(Gain) Loss on extinguishment of debt									(1.0)
General and Administrative Expenses [Member]
Subsidiary Or Equity Method Investee [Line Items]
Gain on sale								4.0
Minimum [Member] \| Contingent Milestone Payment Period [Member] \| Pruvit
Subsidiary Or Equity Method Investee [Line Items]
Asset acquisition contingent payments	5.0
Minimum [Member] \| Contingent Milestone Payments Third [Member] \| Pro2col Health LLC [Member]
Subsidiary Or Equity Method Investee [Line Items]
Contingent payments	5.0
Maximum [Member] \| Contingent Milestone Payment Period [Member] \| Pruvit
Subsidiary Or Equity Method Investee [Line Items]
Asset acquisition contingent payments	25.0
Maximum [Member] \| Contingent Milestone Payments First [Member] \| Pro2col Health LLC [Member]
Subsidiary Or Equity Method Investee [Line Items]
Contingent payments	2.0
Maximum [Member] \| Contingent Milestone Payments Second [Member] \| Pro2col Health LLC [Member]
Subsidiary Or Equity Method Investee [Line Items]
Contingent payments	3.0
Maximum [Member] \| Contingent Milestone Payments Third [Member] \| Pro2col Health LLC [Member]
Subsidiary Or Equity Method Investee [Line Items]
Contingent payments	15.0
China [Member]
Subsidiary Or Equity Method Investee [Line Items]
Goodwill							3.0	2.9
Other operating income							$ 4.8	5.5	10.2
Reclassification [Member]
Subsidiary Or Equity Method Investee [Line Items]
General and administrative expenses								149.8	165.0
Assembled Workforce [Member] \| Pruvit
Subsidiary Or Equity Method Investee [Line Items]
Consideration to acquire assets	0.3
Customer Relationships [Member] \| Pruvit
Subsidiary Or Equity Method Investee [Line Items]
Consideration to acquire assets	4.3
Customer Relationships [Member] \| Link BioSciences Inc [Member]
Subsidiary Or Equity Method Investee [Line Items]
Assets estimated fair value at the acquisition date			0.5
Member compensation Liabilities [Member]
Subsidiary Or Equity Method Investee [Line Items]
Other current liabilities								25.8
Cash outflow								$ 4.6	$ 0.8
Buildings [Member]
Subsidiary Or Equity Method Investee [Line Items]
Estimated useful life							40 years
Furniture, Fixtures and Equipment [Member] \| Minimum [Member]
Subsidiary Or Equity Method Investee [Line Items]
Estimated useful life							3 years
Furniture, Fixtures and Equipment [Member] \| Maximum [Member]
Subsidiary Or Equity Method Investee [Line Items]
Estimated useful life							10 years
Building Improvements [Member] \| Minimum [Member]
Subsidiary Or Equity Method Investee [Line Items]
Estimated useful life							10 years
Building Improvements [Member] \| Maximum [Member]
Subsidiary Or Equity Method Investee [Line Items]
Estimated useful life							15 years
Developed Technology and Software [Member] \| Pruvit \| Property, Plant and Equipment [Member]
Subsidiary Or Equity Method Investee [Line Items]
Consideration to acquire assets	$ 14.4
Manufacturing Facility [Member] \| Link BioSciences Inc [Member] \| Property, Plant and Equipment [Member]
Subsidiary Or Equity Method Investee [Line Items]
Assets estimated fair value at the acquisition date			2.5
Software [Member] \| Link BioSciences Inc [Member] \| Property, Plant and Equipment [Member]
Subsidiary Or Equity Method Investee [Line Items]
Assets estimated fair value at the acquisition date			$ 2.5